Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.69 | N/A | -3.45% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.69 | N/A | -3.45% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current market conditions and reiterated their commitment to navigating through these challenges. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
No specific updates were provided regarding future product launches.
The earnings report indicates that Protagonist Therapeutics is still facing challenges, as evidenced by the missed EPS target. The stock reacted negatively, dropping 4.87%, likely due to investor concerns over the lack of revenue information and future guidance. The management's defensive tone suggests caution moving forward, which may impact investor sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SENTINELONE INC Class A
Mar 14, 2023